Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
4.13
USD
|
-2.13%
|
|
-5.92%
|
-44.64%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
726.2
|
409
|
-
|
-
|
Enterprise Value (EV)
1 |
726.2
|
533.1
|
338.2
|
409
|
P/E ratio
|
-1.37
x
|
-1.35
x
|
-1.02
x
|
-1.29
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
9.77
x
|
EV / Revenue
|
-
|
-
|
-
|
9.77
x
|
EV / EBITDA
|
-
|
-1.28
x
|
-0.77
x
|
-
|
EV / FCF
|
-
|
-1.73
x
|
-0.84
x
|
-0.87
x
|
FCF Yield
|
-
|
-57.9%
|
-119%
|
-115%
|
Price to Book
|
-
|
-1.74
x
|
-14.2
x
|
-
|
Nbr of stocks (in thousands)
|
97,339
|
99,027
|
-
|
-
|
Reference price
2 |
7.460
|
4.130
|
4.130
|
4.130
|
Announcement Date
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
41.86
|
EBITDA
1 |
-
|
-
|
-416.4
|
-437.4
|
-
|
EBIT
1 |
-
|
-422.1
|
-368.4
|
-441.8
|
-506.9
|
Operating Margin
|
-
|
-
|
-
|
-
|
-1,210.93%
|
Earnings before Tax (EBT)
1 |
-
|
-381.6
|
-310.3
|
-413.1
|
-479.2
|
Net income
1 |
-64.77
|
-381.6
|
-310.3
|
-413.1
|
-479.2
|
Net margin
|
-
|
-
|
-
|
-
|
-1,144.66%
|
EPS
2 |
-21.09
|
-5.430
|
-3.054
|
-4.048
|
-3.200
|
Free Cash Flow
1 |
-
|
-
|
-308.5
|
-401.5
|
-470
|
FCF margin
|
-
|
-
|
-
|
-
|
-1,122.77%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/13/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-82.72
|
-102.9
|
-104.9
|
-
|
-
|
-
|
EBIT
1 |
-
|
-42.7
|
-94.42
|
-105.1
|
-82.77
|
-84.63
|
-91.93
|
-101.4
|
-115.9
|
-117.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-26.04
|
-83.94
|
-95.21
|
-34.97
|
-68.06
|
-79.22
|
-96.14
|
-115.9
|
-117.5
|
Net income
1 |
-176.4
|
-26.04
|
-83.94
|
-95.21
|
-34.97
|
-68.06
|
-79.22
|
-96.14
|
-115.9
|
-117.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-8.610
|
-0.4000
|
-0.8700
|
-0.7500
|
-0.3600
|
-0.6867
|
-0.7967
|
-0.9300
|
-1.160
|
-1.170
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/15/23
|
8/14/23
|
11/7/23
|
3/28/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
124
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
70.8
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.2982
x
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-309
|
-402
|
-470
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-80.9%
|
-207%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-2.370
|
-0.2900
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
2.5
|
2.33
|
3
|
Capex / Sales
|
-
|
-
|
-
|
-
|
7.17%
|
Announcement Date
|
4/13/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
4.13
USD Average target price
22.17
USD Spread / Average Target +436.72% Consensus |
1st Jan change
|
Capi.
|
---|
| -44.64% | 409M | | +12.30% | 118B | | +12.15% | 106B | | -8.14% | 23.4B | | -1.69% | 21.78B | | -10.60% | 18.09B | | -41.25% | 16.72B | | -15.33% | 15.97B | | +5.80% | 14.03B | | +28.03% | 11.67B |
Bio Therapeutic Drugs
|